Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
CD276
bladder cancer stem cell
immune checkpoint antigen
urothelial carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
25
03
2022
revised:
22
04
2022
accepted:
26
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
The cell surface molecule CD276 (B7-H3) is an immune checkpoint antigen. The elevated expression of CD276 on tumors contributes to the suppression of anti-tumor T-cell responses and correlates with poor prognosis. The expression of CD276 was explored in vitro on eight urothelial carcinoma cell lines (UM-UC) in comparison to eight normal urothelial cells (NUCs) by RT-qPCR, Western blotting, and flow cytometry. Cell proliferation was enumerated over consecutive passages. The expression of cancer stem cell markers CD24 and CD44, cytokeratins, and vimentin was investigated by immunofluorescence. The expression of CD276 in bladder tumor samples and metastases was explored by immunohistochemistry. Expression of CD276 on cell surfaces was elevated on UM-UCs when compared to NUCs. In UM-UCs, CD276 transcripts correlated moderately positive with CD276 protein expression (ρ = 0.660) and strongly positive with CD276 surface-expression (ρ = 0.810). CD276 mRNA expression (ρ = -0.475) and CD276 protein expression (ρ = -0.417) had a significant negative correlation with proliferation, while a significant correlation between proliferation and cell surface expression was not observed in UM-UCs. The expression of CD276 on UM-UC bladder tumor cell surfaces is elevated. Slow proliferating UM-UC cells express more CD276 mRNA and protein than fast proliferating cells. In patients, slow proliferating CD276
Identifiants
pubmed: 35563359
pii: ijms23094969
doi: 10.3390/ijms23094969
pmc: PMC9100984
pii:
doi:
Substances chimiques
B7 Antigens
0
CD276 protein, human
0
Ligands
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK2543
Références
J Urol. 2011 Sep;186(3):1093-9
pubmed: 21784485
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):327-37
pubmed: 20142235
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Cell Physiol. 2019 Jun;234(6):8381-8395
pubmed: 30417375
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401585
Curr Med Chem. 2020;27(24):4062-4086
pubmed: 31099317
Cancer Res. 2006 Feb 15;66(4):1917-22
pubmed: 16488989
Nature. 2017 Nov 8;551(7679):S34-S35
pubmed: 29117159
Cell Immunol. 2020 Jun;352:104077
pubmed: 32113615
Clin Exp Metastasis. 2003;20(3):195-201
pubmed: 12741678
Eur J Surg Oncol. 2014 Jan;40(1):121-7
pubmed: 24140000
Oncotarget. 2017 Jul 8;8(39):66668-66679
pubmed: 29029546
Front Biosci (Elite Ed). 2011 Jun 01;3(3):989-93
pubmed: 21622107
J Nutr Biochem. 2013 Jun;24(6):1062-9
pubmed: 23159064
Oncogene. 2019 Jan;38(1):88-102
pubmed: 30082909
Cell Mol Immunol. 2020 Mar;17(3):227-236
pubmed: 31611650
Eur J Immunol. 2017 Feb;47(2):385-393
pubmed: 27873300
J Hematol Oncol. 2017 Jan 25;10(1):34
pubmed: 28122590
Oncol Rep. 2018 Nov;40(5):2722-2733
pubmed: 30132557
Signal Transduct Target Ther. 2021 Feb 20;6(1):72
pubmed: 33608497
Sci Rep. 2021 Jul 21;11(1):14849
pubmed: 34290311
Int J Mol Sci. 2019 Jan 13;20(2):
pubmed: 30642115
Semin Cell Dev Biol. 2020 Nov;107:112-125
pubmed: 32317144
Annu Rev Cell Dev Biol. 2008;24:287-308
pubmed: 18590485
Br J Cancer. 2018 Oct;119(8):961-970
pubmed: 30327565
BMC Urol. 2021 Apr 12;21(1):60
pubmed: 33845814
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cell Physiol Biochem. 2016;39(4):1568-80
pubmed: 27626927
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
J Cancer. 2020 Feb 3;11(8):2158-2170
pubmed: 32127943
Stem Cells. 2019 Mar;37(3):382-394
pubmed: 30379377
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Eur Urol. 2020 Feb;77(2):223-250
pubmed: 31753752
Oncol Lett. 2015 Mar;9(3):1420-1424
pubmed: 25663925
J Hematol Oncol. 2017 Jan 11;10(1):12
pubmed: 28077173
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
J Cancer. 2017 Feb 25;8(5):816-824
pubmed: 28382144
J Pathol. 2019 Oct;249(2):151-165
pubmed: 31102277
Cell Stem Cell. 2021 Sep 2;28(9):1597-1613.e7
pubmed: 33945793
J Thorac Dis. 2020 May;12(5):2137-2145
pubmed: 32642118
Immunol Rev. 2017 Mar;276(1):26-39
pubmed: 28258693
Front Oncol. 2021 Mar 26;11:654684
pubmed: 33842369
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Clin Dev Immunol. 2010;2010:683875
pubmed: 21127709
Ann Diagn Pathol. 2020 Jun;46:151483
pubmed: 32143173
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
Clin Cancer Res. 2008 Mar 1;14(5):1478-86
pubmed: 18316572
Cancer Med. 2018 Oct;7(10):5167-5177
pubmed: 30253078
J Urol. 2006 Mar;175(3 Pt 1):1133-7
pubmed: 16469639
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10495-500
pubmed: 18650384
Clin Cancer Res. 2008 Aug 1;14(15):4800-8
pubmed: 18676751
Immunology. 2008 Apr;123(4):538-46
pubmed: 18194267
Cancer Res. 2007 Aug 15;67(16):7893-900
pubmed: 17686830